$4.70
4.08%
Nasdaq, Fri, Nov 15 2024
ISIN
US49720K1016
Symbol
KTRA
Sector
Industry

Kintara Therapeutics Inc Stock price

$4.70
+0.73 18.31% 1M
+2.41 104.86% 6M
+1.73 58.36% YTD
-1.45 23.57% 1Y
-760.75 99.39% 3Y
-669.05 99.30% 5Y
-33,245.30 99.99% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.20 4.08%
ISIN
US49720K1016
Symbol
KTRA
Sector
Industry

Key metrics

Market capitalization $197.54m
Enterprise Value $202.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.45m
Free Cash Flow (TTM) Free Cash Flow $-7.20m
Cash position $4.91m
EPS (TTM) EPS $-75.23
P/E forward negative
Short interest 9.81%
Show more

Is Kintara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Kintara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Kintara Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Kintara Therapeutics Inc:

Buy
100%

Financial data from Kintara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.06 0.06
0% 0%
-
-0.06 -0.06
0% 0%
-
- Selling and Administrative Expenses 5.68 5.68
6% 6%
-
- Research and Development Expense 2.66 2.66
71% 71%
-
-8.40 -8.40
43% 43%
-
- Depreciation and Amortization 0.06 0.06
0% 0%
-
EBIT (Operating Income) EBIT -8.45 -8.45
43% 43%
-
Net Profit -8.32 -8.32
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kintara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kintara Therapeutics Inc Stock News

Neutral
Accesswire
29 days ago
Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapy Lead program entering single Phase 3 accelerated approval registration trial in first half of 2025 for treatment of 1st line Merkel Cell carcinoma under Special Protocol Assessment (SPA) agreement with FDA $31 million fully-funded financing in conne...
Neutral
PRNewsWire
about one month ago
SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kint...
Neutral
PRNewsWire
about one month ago
SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-rev...
More Kintara Therapeutics Inc News

Company Profile

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Head office United States
CEO James Bianco
Employees 11
Founded 2009
Website www.tuhurabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today